| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2002 | Arsenic Trioxide as a Novel Anticancer Agent against Human Transitional Carcinoma - Characterizing Its Apoptotic Pathway | PU, YEONG-SHIAU; HOUR, TZYH-CHYUAN; CHEN, JUN; HUANG, CHAO-YUAN; GUAN, JING-YI | ANTI-CANCER DRUGS | | | |
| 2000 | Characterization of Chemoresistance Mechanisms in a Series of Cisplatin- Resistant Transitional Carcinoma Cell Lines | HOUR, TZYH-CHYUAN; CHEN, JUN; HUANG, CHAO- YUAN; GUAN, JING-YI; LIU, SHIO-HUEI; HSIEH, CHANG-YAO; PU, YEONG-SHIAU; 侯自銓; 陳淳; 黃昭淵; 官靜儀; 呂秀慧; 謝長堯; 蒲永孝 | ANTICANCER RESEARCH | | | |
| 2006 | Differential Expression of Molecular Markers in Arsenic and Non-arsenic-related Urothelial Cancer | Hour, Tzyh-Chyuan; Pu, Yeong-Shiau; Lin, Chia-Chi; Huang, Shi-Wei; Chen, Jun; Chiu, Allen W.; Chen, Chien-Jen; Huang, Chao-Yuan | Anticancer Research | | | |
| 2008 | Down-Regulated Expression of Rhoa in Human Conventional Renal Cell Carcinoma | PU, YEONG-SHIAU; WANG, CHUANG-WEI; LIU, GUANG-YAW; KUO, YI-ZIH; HUANG, CHAO-YUAN; SHUN, CHIA-TUNG; LIN, CHIA-CHI; WU, WEN-JENG; HOUR, TZYH-CHYUAN | ANTICANCER RESEARCH | | | |
| 2008 | Down-Regulated Expression of RhoA in Human Conventional Renal Cell Carcinoma | Pu, Yeong-Shiau; Wang, Chuang-Wei; Liu, Guang-Yaw; Kuo, Yi-Zih; Huang, Chao-Yuan; Kang, Wang-Yi; Shun, Chia-Tung; Lin, Chia-Chi; Wu, Wen-Jeng; Hour, Tzyh-Chyuan | ANTICANCER RESEARCH | | | |
| 2007 | Down-Regulation of Abcd1 May Be Involved in Tumorigenesis of Human Renal Cell Carcinoma | HOUR, TZYH-CHYUAN; YU, HONG-JENG; HUANG, SHU-PIN; PU, YEONG-SHIAU | FEBS JOURNAL | | | |
| 2006 | Epidermal Growth Factor Receptor Inhibitor (Pd168393) Potentiates Cytotoxic Effects of Paclitaxel against Androgen-Independent Prostate Cancer Cells | PU, YEONG-SHIAU; HSIEH, MIN-WEI; WANG, CHUANG-WEI; LIU, GUANG-YAW; HUANG, CHAO-YUAN; LIN, CHIA-CHI; GUAN, JING-YI; LIN, SHINNE- REN; HOUR, TZYH-CHYUAN; 蒲永孝; 謝旻娓; 王壯維; 劉光耀; 黃昭淵; 林家齊; 官靜儀; 林信仁; 侯自銓 | BIOCHEMICAL PHARMACOLOGY | | | |
| 2006 | Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells | Pu, Yeong-Shiau; Hsieh, Min-Wei; Wang, Chuang-Wei; Liu, Guang-Yaw; Huang, Chao-Yuan; Lin, Chia-Chi; Guan, Jing-Yi; Lin, Shinne-Ren; Hour, Tzyh-Chyuan | Biochemical Pharmacology | | | |
| 2004 | Interleukin-6 Is Responsible for Drug Resistance and Anti-Apoptotic Effects in Prostatic Cancer Cells | PU, YEONG-SHIAU; HOUR, TZYH-CHYUAN; CHUANG, SHUANG-EN; CHENG, ANN-LII; LAI, MING-KUEN; KUO, MIN-LIANG; 鄭安理 | PROSTATE | | | |
| 2007 | Weekly paclitaxel and high-dose 5-Fluorouracil plus leucovorin (T-HDFL) in hormone-refractory prostate cancer: in Vitro combined effects and phase II trial | Lin, Chia-Chi; Hsu, Chih-Hung; Hour, Tzyh-Chyuan; Cheng, Ann-Lii; Huang, Chao-Yuan; Huang, Kuo-How; Chen, Jun; Pu, Yeong-Shiau | UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | | | |
